Although this is true for all tumors, it is particularly relevant for prostate cancer, due to factors related with disease heterogeneity and difficulty in assessing disease in bone and interpreting the clinical significance of post-therapy PSA changes in different settings. The gene discussed is KLK3; the disease is Familial prostate cancer.